Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Read original at benzingaStocks · News reference
Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Read original at benzingaPrivate equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
Read original at benzingaDow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
Read original at benzingaThe global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030 at a 16.1% CAGR, driven by regenerative medicine demand, pharmaceutical adoption for drug discovery, reduced animal testing, and AI integration. North America leads with 38% market share, while emerging technologies like 4D bioprinting and organ-on-chip devices expand market boundaries.
Read original at globenewswire-incThe global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.
Read original at globenewswire-incThe global Deep Eutectic Solvents (DES) market is projected to grow from USD 177.64 million in 2024 to USD 735.89 million by 2034, at a CAGR of 15.27%. Growth is driven by increasing demand for sustainable, eco-friendly alternatives to conventional solvents across pharmaceuticals, food processing, and chemical industries. Key players include Proionic GmbH, Merck KGaA, BASF SE, Thermo Fisher Scientific, and Solvay S.A.
Read original at globenewswire-inc